| |
Overall mortality
|
Breast cancer mortality
|
Recurrence
|
|---|
|
Variable
|
HRa
|
95% CI
|
P -value
|
HR
|
95% CI
|
P -value
|
HR
|
95% CI
|
P -value
|
|---|
|
Body mass index, k/m2
| | | | | | | | | |
|
<18.5
|
0.98
|
0.53, 1.79
|
0.945
|
0.95
|
0.48, 1.85
|
0.871
|
0.77
|
0.43, 1.37
|
0.377
|
|
18.5 to 24.9
|
1.00
| | |
1.00
| | |
1.00
| | |
|
25.0 to 29.9
|
0.95
|
0.80, 1.12
|
0.549
|
1.01
|
0.84, 1.22
|
0.905
|
1.03
|
0.89, 1.19
|
0.728
|
|
30.0 to 34.9
|
0.98
|
0.79, 1.20
|
0.814
|
1.02
|
0.81, 1.29
|
0.860
|
1.07
|
0.89, 1.29
|
0.460
|
|
≥35
|
1.35
|
1.06, 1.72
|
0.016
|
1.32
|
1.00, 1.74
|
0.053
|
1.25
|
0.99, 1.57
|
0.052
|
|
Age
| | | | | | | | | |
|
Per 5 years
|
0.92
|
0.87, 0.97
|
0.003
|
0.86
|
0.81, 0.92
|
<0.001
|
0.84
|
0. 80, 0.89
|
<0.001
|
|
Menopausal status
| | | | | | | | | |
|
Postmenopausal
|
1.00
| | |
1.00
| | |
1.00
| | |
|
Premenopausal
|
0.60
|
0.48, 0.74
|
<0.001
|
0.56
|
0.44, 0.71
|
<0.001
|
0.64
|
0.53, 0.77
|
<0.001
|
|
Pathologic primary tumor size
| | | | | | | | | |
|
T1
|
1.00
| | |
1.00
| | |
1.00
| | |
|
T2
|
1.82
|
1.56, 2.32
|
<0.001
|
1.87
|
1.57, 2.22
|
<0.001
|
1.67
|
1.46, 1.91
|
<0.001
|
|
T3
|
1.88
|
1.40, 2.53
|
<0.001
|
2.07
|
1.51, 2.84
|
<0.001
|
1.71
|
1.31, 2.23
|
<0.001
|
|
Histological grade
| | | | | | | | | |
|
1
|
1.00
| | |
1.00
| | |
1.00
| | |
|
2, 3, or unknown
|
1.26
|
1.07, 1.48
|
0.006
|
1.32
|
1.10, 1.58
|
0.003
|
1.24
|
1.07, 1.43
|
0.004
|
|
Type of surgery
| | | | | | | | | |
|
Mastectomy
|
1.00
| | |
1.00
| | |
1.00
| | |
|
Conservative
|
0.82
|
0.70, 0.95
|
0.008
|
0.83
|
0.70, 0.98
|
0.028
|
0.84
|
0.74, 0.96
|
0.011
|
|
Estrogen receptor/progesterone receptor
| | | | | | | | | |
|
Both negative
|
1.00
| | |
1.00
| | |
1.00
| | |
|
Any positive
|
0.56
|
0.48, 0.64
|
<0.001
|
0.51
|
0.44, 0.60
|
<0.001
|
0.66
|
0.57, 0.75
|
<0.001
|
|
Unknown
|
0.85
|
0.51, 1.44
|
0.558
|
0.89
|
0.52, 1.54
|
0.689
|
1.10
|
0.69, 1.75
|
0.699
|
|
Human epidermal growth factor-2 status
| | | | | | | | | |
|
Negative
|
1.00
| | |
1.00
| | |
1.00
| | |
|
Positive
|
1.19
|
1.00, 1.42
|
0.048
|
1.23
|
1.01, 1.49
|
0.037
|
1.23
|
1.05, 1.44
|
0.009
|
|
Unknown
|
1.00
|
0.82, 1.23
|
0.965
|
1.11
|
0.89, 1.38
|
0.361
|
1.09
|
0.91, 1.30
|
0.335
|
|
Undertreatment
| | | | | | | | | |
|
None
|
1.00
| | |
1.00
| | |
1.00
| | |
|
Epirubicine <85%
|
2.36
|
1.18, 4.72
|
0.015
|
3.06
|
1.47, 6.36
|
0.003
|
1.84
|
0.93, 3.63
|
0.078
|
|
Cyclophosph <85%
|
0.86
|
0.35, 2.13
|
0.74
|
0.93
|
0.34, 2.53
|
0.880
|
1.31
|
0.58, 2.95
|
0.519
|
|
Fluorouracil <85%
|
0.64
|
0.30, 1.34
|
0.235
|
0.45
|
0.19, 1.07
|
0.069
|
0.50
|
0.26, 0.99
|
0.046
|
|
Doxorubicin <85%
|
1.86
|
0.89, 3.88
|
0.097
|
1.86
|
0.82, 4.22
|
0.134
|
1.29
|
0.63, 2.64
|
0.478
|
|
Docetaxel <85%
|
0.84
|
0.46, 1.53
|
0.559
|
0.70
|
0.35, 1.40
|
0.315
|
0.75
|
0.44, 1.28
|
0.294
|
|
Paclitaxel <85%
|
1.37
|
0.90, 2.09
|
0.147
|
1.06
|
0.62, 1.81
|
0.824
|
1.15
|
0.78, 1.70
|
0.491
|
- Models were adjusted for all the other variables in the table. aHazard ratio, 95% CI and P-value adjusted for study, treatment regimen and the rest of variables in the table.
